Professional development
Kabita Nanda, MD
Seattle Children's Hospital / University of Washington
Seattle, Washington, United States
Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing), site PI for 2 studies, but do not receive direct support for this effort (Ongoing); Pfizer: Grant/Research Support (Terminated), site PI 1 study completed 10/2022, but did not receive direct support for this effort (Terminated)
Pui Lee, MD;PhD
Boston Children's Hospital
Newton, Massachusetts, United States
Disclosure information not submitted.
The speakers will discuss FDA’s approach to ensuring the availability of safe and effective drugs and highlight new initiatives at FDA relevant to pediatric rheumatology. This session will review the efficacy and safety of recent approvals for the treatment of pediatric rheumatic diseases, the increasing number of biosimilars and interchangeables, and the data to support these approvals.
Speaker: Ozlem Belen, MD – FDA
Speaker: Suzette Peng, MD – FDA